News Autoimmune disease biotech Odyssey sets terms for $225m IPO After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.
News Lila Sciences' $235m first round, and other biofinancings Recent biotech financings include big rounds for Lila Sciences, Odyssey, and Ollin, with ARTHEx, Dualitas, and YolTech also in on the action.
News Two more biotechs join IPO waiting list Odyssey and Sionna have filed to carry out IPOs on the Nasdaq, following after Metsera and Maze which filed earlier in January.
News Odyssey Therapeutics $168 million Series B financing oversub... Biotech company Odyssey Therapeutics, Inc.
Oncology ASCO 2026: Can a blood test spot cancer early? with Dr Peter... Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.